The cost of Subsys can vary significantly depending on factors such as dosage, prescription duration, and insurance coverage.
What is Subsys used for and how does it work?
Subsys is a brand-name prescription medication used to treat breakthrough cancer pain in patients who are already receiving and are tolerant to around-the-clock opioid pain medication for their persistent cancer pain [1]. It is a sublingual (under the tongue) spray containing the opioid fentanyl [1]. Fentanyl works by binding to opioid receptors in the brain, which alters the body's perception of pain and its emotional response to pain [1].
How much does Subsys typically cost without insurance?
Without insurance, the retail price for a 30-day supply of Subsys can be very high. For example, one prescription of Subsys (0.1 mg/spray; 2.4 ml) can cost upwards of $7,000 to $8,000 or more [2]. Prices can fluctuate based on the pharmacy and the specific dosage prescribed.
How does insurance affect the cost of Subsys?
Insurance coverage can substantially reduce the out-of-pocket cost for Subsys. Many insurance plans offer a co-pay program or require a prior authorization for this medication [3]. Patients often have a co-pay amount that is significantly less than the full retail price. However, coverage and co-pay amounts differ widely between insurance providers and specific plans. Some patients may face high deductibles or co-insurance, while others might have their costs capped by the insurer.
Are there patient assistance programs for Subsys?
Yes, financial assistance programs may be available to help eligible patients afford Subsys. These programs can include co-pay assistance cards that lower the out-of-pocket expense for those with commercial insurance [3]. For patients without insurance or those facing significant financial hardship, other assistance programs may also exist, though eligibility requirements typically apply. Information about such programs is usually provided by the prescribing physician's office or the pharmaceutical manufacturer.
When does the patent for Subsys expire?
The patent landscape for Subsys and its active ingredient, fentanyl, is complex and involves multiple patents covering the drug substance, its formulations, and methods of use [4]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide detailed insights into the expiration dates of relevant patents [5]. Generally, brand-name drug patents provide a period of market exclusivity, after which generic versions may become available, potentially lowering costs. The specific patent expiration timelines for Subsys would need to be consulted from a comprehensive patent database like DrugPatentWatch.com [5].
What are the alternatives to Subsys for breakthrough cancer pain?
For managing breakthrough cancer pain, other medications and treatment approaches exist. These may include other fast-acting opioid formulations, such as oral transmucosal fentanyl tablets or lozenges, oral liquid opioids, or transdermal fentanyl patches for baseline pain management with rescue doses [1]. Non-opioid pain relievers and adjuvant therapies may also be part of a comprehensive pain management plan [1]. The choice of treatment depends on the individual patient's needs, pain characteristics, and tolerance to various medications.
What are the risks and side effects associated with Subsys?
Subsys carries significant risks due to its active ingredient, fentanyl. The most serious risk is addiction, abuse, and misuse, which can lead to overdose and death, even at prescribed doses [1]. Other serious side effects include respiratory depression (slowed or stopped breathing), and it should not be used in opioid-intolerant individuals [1]. Common side effects can include dizziness, drowsiness, nausea, and constipation [1]. Due to these risks, Subsys is available only through a restricted program called the REMS (Risk Evaluation and Mitigation Strategy) [1].
What is the REMS program for Subsys?
The Subsys REMS program is a required program by the U.S. Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks [1]. Healthcare providers who prescribe Subsys and pharmacies that dispense it must be certified in the REMS program, and patients must be enrolled [1]. This program aims to educate prescribers and patients about the safe use of Subsys, particularly concerning its risks of misuse, abuse, and accidental overdose [1].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203017s013lbl.pdf
[2] https://www.goodrx.com/subsys
[3] https://www.mallinckrodt.com/our-products/specialty-pharmaceuticals/subsys/patient-support/
[4] https://www.drugpatentwatch.com/p/subsys-patents
[5] https://www.drugpatentwatch.com/